Research shows savings can be achieved if Ugandan company provides HIV drugs to employees

July 12, 2000

Researchers have found that it may be cost-effective for Ugandan companies to provide HIV drugs to their employees with HIV when they get sick.

The study team, headed by a University of California, San Francisco AIDS researcher, developed an economic model that looked at the HIV-related costs to operating the business, including limited medical care, lost productivity due to illness, disability payments, new worker training, and death benefits paid to the employee's family. These costs were then compared with the cost of a more intensive preventive care program, accounting for anticipated savings in HIV treatment costs.

Study results were reported today (July 13) at the XIII International AIDS Conference in Durban, South Africa.

The model used generic estimates from published studies and looked at companies with over 500 employees. A case study of a major Ugandan corporation will be used to update the estimates.

"These preliminary results suggest that it may be in the economic self interest of Ugandan businesses to play a major role in treating their HIV-infected employees. Businesses are potentially important players if they can determine the circumstances in which it makes sense for them to step up to the plate," said lead investigator Elliot Marseille, DrPH, MPP, a researcher at the UCSF AIDS Research Institute and the director of Health Strategies International.

He cautioned, "This is no panacea. The private sector won't be able to provide everything needed and should not be required to. Since many of the benefits of treating HIV-infected workers accrue to the society at large and not just to employers, there is a strong rationale for continued public sector involvement as well. Also, the specific situation may vary for different companies, and this is something we are trying to understand better through the case studies. "

The analysis focused on the costs and benefits of providing highly active anti-retroviral treatment (HAART) and the preventive drug cotrimoxazole (PCTMX) to employees with HIV once they become symptomatic. The model reflects the recent 85 percent price reductions in the cost of antiretrovirals for developing countries.

The economic model factored in several costs generally experienced by a Ugandan company due to employees with HIV. African companies typically do not provide health insurance, according to Marseille. Instead, they either set up their own clinics or contract with a clinic to provide health care to employees. The company incurs costs to treat opportunistic infections experienced by employees with HIV at the clinics.

The model quantifies the lost productivity of the days lost by non-disabled workers due to opportunistic infections and days lost between the total disability of the worker and the start date of his/her replacement hire. The model also quantifies the training costs for the new hire and the initial diminished productivity of the replacement as the new worker learns the job. The other cost borne by the company is the cost of death benefits, standard benefits offered by most Ugandan companies, Marseille said.

These costs can include the cost of the employee's funeral, a lump sum benefit paid to the deceased's family, and travel expenses for the transport of the deceased and his/her family to the deceased's place of birth for burial. These costs taken together are estimated to cost a company annually $327 per skilled employee and $185 per unskilled worker.

The cost of providing only PCTMX plus the gain in productivity and diminished incidents of death create annual cost savings of $74 per skilled employee and $42 per unskilled employee. The cost of HAART at the 85 percent price reduction and PCTMX saves the company $86 per skilled employee. HAART and PCTMX for an unskilled worker ends up costing the company $29 per life-year gained.

The study concludes that it saves Ugandan company money to fund either the prophylactic PCTMX alone or along with HAART for skilled workers. Providing PCTMX alone to unskilled workers saves money while providing PCTMX with HAART nears the break-even point.
Study co-authors are James G. Kahn, MD, MPH, of the UCSF AIDS Research Institute and UCSF Institute for Health Policy Studies, and Joseph Saba, MD, Axios International.

University of California - San Francisco

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to